ChemComm

COMMUNICATION

Enantioselective total synthesis of virosaine A and bubbialidine†‡

Hideki Miyatake-Ondozabal, Linda M. Bannwart and Karl Gademann*

The first enantioselective total syntheses of virosaine A and bubbialidine are described. Key transformations include the formation of a tetracyclic intermediate *via* an intramolecular aza-Michael addition, generation of a *N*-hydroxy-pyrrolidine through a Cope elimination and an intramolecular [1,3]-dipolar cycloaddition to generate a complex 7-oxa-1-azabicyclo[3.2.1]octane ring system.

The securinega alkaloids are a family of bridged tetracyclic natural products occurring in the plants of the *Securinega*, *Phyllanthus*, *Flueggea* and other genera in the Euphorbiaceae family.[1] Recently, two new birdcage-shaped alkaloids with unprecedented skeletal structures were isolated, namely virosaine A (**1**) and virosaine B (**2**), from the twigs and leaves of *Flueggea virosa* (Fig. 1).[2] The unique structural features of these pseudoenantiomers are characterized by their densely functionalized, stereochemically complex architecture featuring an unusual tetracyclic core incorporating a trihydro-1,2-oxazine ring. Neither **1** nor **2** showed cytotoxic activity against selected cancer cell lines (MCF-7, MDA-MB-231, HepG2, HepG2/ADM, HL-60, K562 and Hep2).[2]

Among this family of natural products, securinine (**3**) is the most abundant and widely spread alkaloid possessing an impressive range of biological activity including neurotransmitter gamma-aminobutyric acid (GABA) receptor antagonism,[3] *in vivo* CNS activity and anti-malarial and anti-bacterial activities.[4,5] Due to its remarkable biological activities and intriguing molecular structure, numerous total syntheses have been reported to date.[1b,6] Conversely, a related yet much rarer securinega alkaloid (+)-phyllantidine (**4**) has a similar cyclic hydroxylamine scaffold to virosaines A (**1**) and B (**2**) and only one total synthesis has been published due to its complex architecture.[7] During the preparation of this manuscript, the first total synthesis of virosaine B was reported by Yang, Li and coworkers.[8] Two other putatively related

Department of Chemistry, University of Basel, St. Johanns-Ring 19, Basel 4056, Switzerland. E-mail: karl.gademann@unibas.ch; Tel: +41 612671144

† Dedicated to Professor Dr Christoph Tamm on the occasion of his 90th birthday.

‡ Electronic supplementary information (ESI) available: For experimental procedures and compound characterization of all new compounds. See DOI: 10.1039/c3cc38783f


**Fig. 1** Virosaines A, B and examples of related alkaloids.

alkaloids bubbialidine (**5**) and bubbialine (**6**) were isolated from the leaves of *Zygogynum pauciflorum* by Potier *et al.* in 1990.[9] There is no reported publication for the synthesis of virosaine A and bubbialidine to date. In this communication, we report the first total syntheses of virosaine A (**1**) and bubbialidine (**5**).

Our brief retrosynthetic analysis is illustrated in Scheme 1. The main synthetic strategies are the vinylogous Mannich reaction, an intramolecular aza-Michael addition, a late-stage regioselective oxidation of the pyrrolidine moiety to the nitrone and the subsequent intramolecular [1,3]-dipolar cycloaddition. Inspired by the proposed biosynthesis of virosaines suggested by Zhang, Ye and coworkers,[2] we envisaged that nitrone **7** should undergo a stereoselective intramolecular cycloaddition to form the complex tetracyclic core **1**, creating three new stereogenic centres. A regioselective oxidation could be achieved in *N*-hydroxy-pyrrolidine **8** leading to **7**. Following a synthetic strategy described by Magnus *et al.*,[10] oxidation precursor **8** should be available from tetracycle **9** through an *N*-oxidation–Cope elimination sequence. An intramolecular aza-Michael addition of pyrrolidinyl-furanone **10** would allow the formation of **9**, which will serve as a masked alkene intermediate enabling *N*-oxidation in the next step. Finally, a vinylogous Mannich reaction between aminol **11** and furanone **12** should provide the key intermediate **10** after *t*-butyloxycarbonyl (Boc) deprotection.

**Scheme 1** Retrosynthesis of virosaine A and bubbialidine.

The preparation of silyl-protected aquilegiolide (+)-**12** was carried out following three reported publications (Schemes 2 and 3).[11] The synthesis started with commercially available 1,4-cyclohexadiene **13**. A three step procedure involving mono-epoxidation, ring-opening with cyanomethyllithium and acetylation gave the racemic acetate (±)-**14** in 22% yield. Enzymatic kinetic resolution was then employed to generate enantiomerically enriched alcohol (−)-**15** and acetate (+)-**14** with 94.6% ee and 96.0% ee, respectively.[11a]

Treatment of alcohol (−)-**15** under basic conditions triggered the hydrolysis of the nitrile functionality (Scheme 3). Subsequent acid catalysed lactonisation with *p*-toluenesulfonic acid gave lactone (−)-**16** in 80% yield over two steps. Following phenyl-selenation and oxidative elimination, butenolide (−)-**17** was accessed in moderate yield.[11b] The silyl protected aquilegiolide (+)-**12** was obtained by diastereoselective epoxidation (dr = 5 : 1), base-induced epoxide opening and silyl protection in good yields over three steps.[11c]

The enantioselective synthesis of virosaine A (**1**) is described in Scheme 4. The first key transformation, a vinylogous Mannich reaction,[12] between (+)-**12** and aminol **11**[13] was achieved using triisopropylsilyl triflate as a Lewis acid, an elegant methodology reported by Busqué and coworkers.[11c] This resulted in the formation of solely two diastereoisomers (among the four possible) in


**Scheme 2** Enantioselective synthesis of (−)-**15** and (+)-**14**.

Scheme 3 Synthesis of butenolide **12**.

1 : 1 ratio in a yield of 90%. Pleasingly, the two isomers were separable by column chromatography allowing clean isolation of the desired adduct (−)-**18**. The Boc group was smoothly removed using a hydrogen chloride solution to give (−)-**19** in a quantitative yield. To our surprise, the treatment of HCl salt (−)-**19** with potassium hydrogenphosphate at elevated temperature facilitated an intramolecular aza-Michael addition[14] to furnish the tetracycle (−)-**9** in a remarkable yield of 90%.

This transformation enabled efficient formation of *N*-oxide **20** (supported by ^{1}H-NMR characterization) in the next step using *m*-chloroperbenzoic acid and the alkene functionality was

Scheme 4 Enantioselective synthesis of virosaine A (**1**).

Scheme 5 Enantioselective synthesis of bubbialidine (**5**).

revealed under slightly acidic conditions to yield *N*-hydroxy-pyrrolidine (−)-**8** in 77% yield over two steps.[15] The next step was the construction of the nitrone unit **7** utilizing a convenient and mild method developed by Mukaiyama and coworkers.[16]

Gratifyingly, the use of *N*-*t*-butylbenzenesulfinimidoyl chloride **21**[17] at −78 °C resulted in a complete regioselective formation of nitrone **7** due to steric encumbrance and an immediate intramolecular [1,3]-dipolar cycloaddition[15a,18,19] was observed. Finally, the removal of silyl group was performed using tetrabutylammonium fluoride to give virosaine A (**1**) in a good yield of 81% over two steps. The synthetic virosaine A (**1**) displayed identical physical and spectroscopic data to those reported in the literature.[2] In addition, the first synthesis of bubbialidine (**5**) was also accomplished by silyl deprotection of tetracycle (−)-**9** to give the target natural product in 92% yield (Scheme 5). The synthetic sample displayed identical physical and spectroscopic data to the reported values.[9]

In summary, we report the first enantioselective total syntheses of virosaine A (**1**) and bubbialidine (**5**). The synthesis of virosaine A was achieved in 18 steps whereas bubbialidine was synthesized in 15 steps starting from readily available material. Our synthetic strategy can be highlighted by the intramolecular aza-Michael addition for the construction of the tetracycle (−)-**9**, Cope-elimination for a late-stage oxidation of the pyrrolidine unit, and an intramolecular cycloaddition reaction to build the 7-oxa-1-azabicyclo[3.2.1]octane ring core. Further application of this approach towards related natural products is currently under investigation.

Notes and references

1 (a) V. Snieckus, in *The Alkaloids*, ed. R. H. F. Manske, Academic Press, New York, 1973, vol. 14, pp. 425–503; (b) S. M. Weinreb, *Nat. Prod. Rep.*, 2009, **26**, 758; (c) J. A. Beutler and A. N. Brubaker, *Drugs Future*, 1987, **12**, 957–976.
2 B.-X. Zhao, Y. Wang, D.-M. Zhang, X.-J. Huang, L.-L. Bai, Y. Yan, J.-M. Chen, T.-B. Lu, Y.-T. Wang, Q.-W. Zhang and W.-C. Ye, *Org. Lett.*, 2012, **14**, 3096.
3 D. Rognan, T. Boulanger, R. Hoffmann, D. P. Vercauteren, J.-M. Andre, F. Durant and C.-G. Wermuth, *J. Med. Chem.*, 1992, **35**, 1969.
4 (a) E. Galvez-Ruano, M. H. Aprison, D. H. Robertson and K. B. Lapkowitz, *J. Neurosci. Res.*, 1995, **42**, 666; (b) H. Weenen, M. H. H. Nkunya, D. H. Bray, L. B. Mwasumbi, L. S. Kinabo, V. A. Kilimali and J. B. Wijnberg, *Planta Med.*, 1990, **56**, 371; (c) J. L. Mensah, I. Lagarde, C. Ceschin, G. Michel, J. Gleye and

I. Fouraste, *J. Ethnopharmacol.*, 1990, **28**, 129; (d) H. Tatematsu, M. Mori, T.-H. Yang, J.-J. Chang, T. T.-Y. Lee and K.-H. Lee, *J. Pharm. Sci.*, 1991, **80**, 325.
5 For an early review of the biological activities of these alkaloids, see: J. A. Beutler and A. N. Brubaker, *Drugs Future*, 1987, **12**, 957.
6 (a) S. Saito, H. Yoshikawa, Y. Sato, H. Nakai, N. Sugimoto, Z. Horii, M. Hanaoka and Y. Tamura, *Chem. Pharm. Bull.*, 1966, **14**, 313; (b) T. Honda, H. Namiki, M. Kudoh, N. Watanabe, H. Nagase and H. Mizutani, *Tetrahedron Lett.*, 2000, **41**, 5927; (c) S. Liras, J. E. Davoren and J. Bordner, *Org. Lett.*, 2001, **3**, 703; (d) B. Dhudshia, B. F. T. Cooper, C. L. B. Macdonald and A. N. Thadani, *Chem. Commun.*, 2009, 463.
7 C. A. Carson and M. A. Kerr, *Angew. Chem., Int. Ed.*, 2006, **45**, 6560.
8 H. Wei, C. Qiao, G. Liu, Z. Yang and C.-C. Li, *Angew. Chem., Int. Ed.*, 2013, **52**, 620.
9 A. Ahond, J. Guilhem, J. Hamon, J. Hurtado, C. Poupat, J. Pusset, M. Pusset, T. Sévenet and P. Potier, *J. Nat. Prod.*, 1990, **53**, 875. For the isolation of related natural products, see: (a) P. J. Houghton, T. Z. Woldemariam, S. O'Shea and S. P. Thyagarajan, *Phytochemistry*, 1996, **43**, 715; (b) J. R. Patela, P. Tripathib, V. Sharmaa, N. S. Chauhana and V. K. Dixit, *J. Ethnopharmacol.*, 2011, **138**, 286.
10 P. Magnus, J. Ródriguez-López, K. Mulholland and I. Matthews, *Tetrahedron*, 1993, **49**, 8059.
11 (a) N. Kato, M. Inada, H. Sato, S. Ito, M. Shoji and M. Ueda, *Tetrahedron Lett.*, 2007, **48**, 7702; (b) G. Audran and K. Mori, *Eur. J. Org. Chem.*, 1998, 57; (c) G. G. Bardaji, M. Canto, R. Alibes, P. Bayon, F. Busqué, P. De March, M. Figueredo and J. Font, *J. Org. Chem.*, 2008, **73**, 7657.
12 For applications of vinylogous Mannich reactions to alkaloid synthesis, see: (a) S. Martin and A. Liras, *J. Am. Chem. Soc.*, 1993, **115**, 10450; (b) S. F. Martin, C. W. Clark and J. W. Corbett, *J. Org. Chem.*, 1995, **60**, 3236; (c) S. F. Martin, C. W. Clark, M. Ito and M. Mortimore, *J. Am. Chem. Soc.*, 1996, **118**, 9804; (d) S. F. Martin and S. K. Bur, *Tetrahedron*, 1999, **55**, 8905; (e) S. F. Martin, K. J. Barr, D. W. Smith and S. K. Bur, *J. Am. Chem. Soc.*, 1999, **121**, 6990. For a review of the Mannich reaction, see: (f) M. Arend, B. Westermann and N. Risch, *Angew. Chem., Int. Ed.*, 1998, **37**, 1045; (g) S. K. Bur and S. F. Martin, *Tetrahedron*, 2001, **57**, 3221.
13 S. Peixoto, T. M. Nguyen, D. Crich, B. Delpech and C. Marazano, *Org. Lett.*, 2010, **12**, 4760.
14 For recent reviews in this area, see: (a) D. Enders, C. Wang and J. X. Liebich, *Chem.–Eur. J.*, 2009, **15**, 11058; (b) P. R. Krishna, A. Sreeshailam and R. Srinivas, *Tetrahedron*, 2009, **65**, 9657; (c) J. Wang, P. Li, P. Y. Choy, A. S. C. Chan and F. Y. Kwong, *ChemCatChem*, 2012, **4**, 917.
15 For examples of synthesis of *N*-hydroxy-pyrrolidines through Cope elimination, see: (a) J. J. Tufariello, *Acc. Chem. Res.*, 1979, **12**, 396; (b) I. A. O'Neil, E. Cleator and D. J. Tapolczay, *Tetrahedron Lett.*, 2001, **42**, 8247; (c) I. A. O'Neil, E. Cleator, V. E. Ramos, A. P. Chorlton and D. J. Tapolczay, *Tetrahedron Lett.*, 2004, **45**, 3655; (d) G. L. Ellis, I. A. O'Neil, V. E. Ramos, S. B. Kalindjian, A. P. Chorlton and D. J. Tapolczay, *Tetrahedron Lett.*, 2007, **48**, 1687.
16 J. Matsuo, T. Shibata, H. Kitagawa and T. Mukaiyama, *ARKIVOC*, 2001, 58, part (x).
17 For other application of this reagent in organic synthesis, see: (a) T. Mukaiyama, J. Matsuo and M. Yanagisawa, *Chem. Lett.*, 2000, 1072; (b) T. Mukaiyama, A. Kawana, Y. Fukuda and J. Matsuo, *Chem. Lett.*, 2001, 390; (c) J. Matsuo, D. Iida, K. Tatani and T. Mukaiyama, *Bull. Chem. Soc. Jpn.*, 2002, **75**, 223; (d) N. Z. Burns, I. Krylova, R. N. Hannoush and P. S. Baran, *J. Am. Chem. Soc.*, 2009, **131**, 9172.
18 (a) R. Huisgen, *Angew. Chem., Int. Ed. Engl.*, 1963, **2**, 565; (b) R. Huisgen, *J. Org. Chem.*, 1968, **33**, 2291; (c) D. St. C. Black, R. F. Crozier and V. C. Davis, *Synthesis*, 1975, 205. For application of intramolecular 1,3-dipolar cycloaddition in organic synthesis, see the excellent reviews by: (d) A. Padwa, *Angew. Chem., Int. Ed. Engl.*, 1976, **15**, 123; (e) A. Padwa and A. M. Schoffstall, *Adv. Cycloaddit.*, 1990, **2**, 1; (f) V. Naira and T. D. Suja, *Tetrahedron*, 2007, **63**, 12247.
19 For the preparation of functionalized isoxazolidines using Cope elimination–intramolecular nitrone cycloaddition, see: I. A. O'Neil, V. E. Ramos, G. L. Ellis, E. Cleator, A. P. Chorlton, D. J. Tapolczay and S. B. Kalindjian, *Tetrahedron Lett.*, 2004, **45**, 3659.